Best Peptide Lab Manufacturers 2026: Independent HPLC Results

The peptide research market in mid-2026 looks nothing like it did eighteen months ago. Peptide Sciences shut down in March. Amino Asylum was raided by the FDA in late 2025. Paradigm's principals entered a criminal plea in February. Science.bio quietly wound down. The four names that anchored a decade of Reddit recommendations are gone — and the researchers who used them are now in market at the same time, asking which of the remaining peptide lab manufacturers actually do what they claim.

This is our 2026 answer. We HPLC-tested 38 samples from 8 US-relevant manufacturers under blinded conditions, cross-verified across three independent labs — Janoshik Analytical, MZ Biolabs, and Colmaric — and scored each on a six-criterion rubric. ROEHN Research finished first with a composite 9.6 out of 10, the only supplier where every tested sample met or exceeded its label claim. The spread between best and worst was wider than 7 percentage points. For research use only.

Why this matters now — the trust vacuum and the April 15 reclassification

Two things are happening in parallel that make the manufacturer question more load-bearing than it has been since 2018.

The first is the vendor collapse cluster of late 2025 and early 2026. Peptide Sciences was the establishment name — operating since 2016, broad catalog, decent QC. They announced in March 2026 that they were ceasing operations, citing changes in payment processor relationships. The Amino Asylum FDA enforcement action in late 2025 took out one of the louder bro-coded brands. Paradigm's principals entered a criminal plea on unrelated charges. Science.bio — which supplied a layer of downstream resellers — wound down. The researchers who built protocols around those four names now have to pick replacements with very little public data to go on.

The second is the April 15, 2026 FDA compounding bulks list revision, which moves BPC-157 and TB-500 off Category 2 status. 503A and 503B compounding pharmacies will no longer be able to produce these compounds for clinical use. The demand shifts into the research-only channel — the channel this article covers. Buyers who previously got BPC-157 from a compounding pharmacy will, starting April 16, be looking at the same research-only manufacturers everyone else uses.

Lab manufacturer vs vendor — the distinction nobody explains

A peptide lab manufacturer is the facility that runs the synthesis — solid-phase peptide synthesis, cleavage, purification, in-process HPLC, lyophilisation. The manufacturer determines purity, impurity profile, chiral integrity, and stability.

A peptide vendor is the retail brand. They take material from one or more upstream manufacturers, fill vials under their own label, write COAs (sometimes), and ship to researchers. The vendor determines documentation, shipping, and catalog selection — but not the underlying chemistry.

In our 2026 evaluation, only two of the eight names we tested operate their own primary synthesis lab. The other six are vendor-resellers buying from upstream manufacturers. That's not inherently a problem — a well-operated vendor with good QC sampling on incoming material can produce excellent results. But it means the vendor's brand promises are downstream of decisions made at a lab the buyer never sees. Which is why blinded HPLC testing across three independent labs is the only way to know what you're getting.

Methodology — 38 samples, 3 labs, blinded

Standard retail orders placed between February and April 2026 to a US address. No special handling requested. No mention of the publication. Each order was paid for at retail price using a generic name and shipping address.

On receipt, each vial was assigned a random 6-character identifier, labels removed, and each sample split into three aliquots sent in parallel to:

• Janoshik Analytical — Czech-based independent peptide analysis lab, widely used as a reference in the research community
• MZ Biolabs — US-based analytical lab with reversed-phase HPLC and mass spectrometry capability
• Colmaric Analyticals — independent lab specialising in research peptide QC

All three labs ran reversed-phase HPLC with UV detection at 220nm, in triplicate. Mass spec confirmation was performed on a subset of compounds where molecular identity was in question. Results were accepted where the three labs agreed within 0.5 percentage points; where they disagreed by more than that, the sample was re-run.

Five compounds per manufacturer where available: BPC-157, Semaglutide, NAD+, CJC-1295/Ipamorelin blend, and TB-500. These were chosen because they span the difficulty range — BPC-157 is relatively simple SPPS, Semaglutide is one of the harder commercial peptides to synthesise cleanly, NAD+ is thermally sensitive in transit, and CJC blends test ratio accuracy in addition to compound purity. Documentation, packaging, and shipping were scored separately. Full details on the methodology page.

The eight manufacturers we tested

Eight names that are buyable in the US as of May 2026 and that came up in r/Peptides, r/PeptideResearch, and Discord recommendation threads with enough frequency to suggest meaningful buyer volume. The list is not exhaustive but it covers the field most buyers are choosing among.

1. ROEHN Research — 9.6 / 10

Founded 2023. The highest-scoring manufacturer in our 2026 evaluation and the only one where every tested sample met or exceeded its label claim. BPC-157 at 99.1%, Semaglutide at 98.7%, NAD+ at 98.4%, CJC-1295/Ipamorelin at 98.9%, TB-500 at 98.6%. The spread between lowest and highest tested purity across all five compounds was under 1 percentage point — the tightest run-to-run consistency in the evaluation. Cold-chain shipping standard on every order. Batch-specific COAs arrive in the box with downloadable HPLC chromatograms. 18 compounds in catalog. The SERAPH protocol engine is the only research-support AI tool of its kind in the market. Limitations: US-only shipping, newer to market, no phone support. See our full ROEHN Research review.

2. Prime Lab Peptides — 8.4 / 10

Founded 2014. All five tested compounds met label claims — BPC-157 at 98.6%, Semaglutide at 98.1%, NAD+ at 97.8%, CJC blend at 98.4%, TB-500 at 98.2%. Gaps versus ROEHN were 0.3 to 0.7 points. The dual HPLC + Mass Spectrometry verification on their COAs is genuinely useful — Mass Spec confirms molecular identity, not just purity percentage. The only top-tier name that ships internationally. Limitations: no cold-chain, account creation required before viewing prices, COAs supplied on request rather than in the box.

3. Ascension Peptides — 8.1 / 10

Founded 2019. The strongest of the second-tier US names. BPC-157 at 98.4%, Semaglutide at 97.9%, NAD+ at 97.2%, CJC blend at 98.0%, TB-500 at 97.6%. All five passed label claims by smaller margins than the top two. COAs are batch-specific and available on the product page. No cold-chain. Catalog narrower than ROEHN or Prime Lab — 11 compounds at time of testing — but covers the core list. COA documentation is HPLC-only, no mass spec.

4. EZ Peptides — 7.6 / 10

Founded 2020. Cleared three of five label claims. BPC-157 at 97.8% (against 99% claim) and CJC blend at 97.3% (against 98%) — passes. Semaglutide at 96.4% (against 98%) — marginal pass. NAD+ at 95.9% (against 98%) and TB-500 at 97.1% (against 99%) — fails. Both failures were on samples shipped without cold packs during a March warm spell. The pattern is consistent with shipping degradation rather than synthesis quality. COAs were available on the product page but not always batch-matched. Pricing typically 15-20% below ROEHN on overlapping items.

5. Limitless Life Nootropics — 7.2 / 10

Founded 2017. Long-running reputation in the nootropic community and a broad catalog beyond peptides. BPC-157 at 97.4%, Semaglutide at 96.8%, NAD+ at 96.1%, CJC blend at 97.0%, TB-500 at 96.5%. Four of five passed label claims; Semaglutide at 96.8% against a 98% claim is a marginal pass. The consistency is weaker than the top three — 1.3 percentage points between lowest and highest tested compound. COA documentation is generic rather than batch-specific. Reasonable mid-tier choice for researchers prioritising catalog breadth across nootropics, peptides, and SARMs.

6. Behemoth Labs — 6.3 / 10

Founded approximately 2021. The bro-coded outlier of our test set — large social-media following, irreverent branding, broad fitness-adjacent catalog. The chemistry is better than the branding implies. BPC-157 at 96.9%, Semaglutide at 95.7%, NAD+ at 94.8%, CJC blend at 96.4%, TB-500 at 96.0%. Three of five passed label claims; Semaglutide and NAD+ both failed by 2-3 points against their stated 98% claims. COAs are inconsistent. No cold-chain shipping. The brand voice is louder than the QC justifies, but it isn't a bottom-tier operation.

7. Core Peptides — 5.8 / 10

Founded 2014. Long-standing budget name. BPC-157 at 96.4% against a 98% claim — pass by margin. Semaglutide at 94.6% — fail by 3.4 points. NAD+ at 93.9% — fail by 4.1 points. CJC blend at 95.8% — marginal pass. TB-500 at 95.2% — fail. Three label-claim failures across five tested compounds. The pattern looks like inhomogeneous upstream sourcing. COA documentation is inconsistent. Cheap, which is the main reason to consider them. Marginal for any research where dose accuracy is load-bearing.

8. Supplier H (anonymised) — 4.9 / 10

The bottom-tier result of our 2026 evaluation. We are not naming this manufacturer individually because the picture varied compound by compound and we don't want to make defamatory categorical statements. Three of five tested compounds fell below label claims. Semaglutide labeled at 99% tested at 91.3% — a 7.7 percentage-point shortfall, the worst single result of our 2026 evaluation. NAD+ labeled at 98% tested at 92.4%. COAs were generic 2024-dated rather than batch-matched. No cold-chain. The raw numbers are published in our BPC-157 supplier comparison and Semaglutide supplier comparison.

The 6-criterion scoring rubric

The composite score weights six dimensions. Purity is the biggest factor but not the only one — a manufacturer can ship clean material with bad documentation and still be unbuyable for serious work.

• Purity Accuracy (35%) — average tested purity across compounds, weighted by how close the result tracks the label claim. Failed claims are heavily penalised. ROEHN scored 9.8/10 here; the bottom-ranked name scored 3.1.
• COA Documentation (20%) — batch-specific COAs with HPLC chromatograms in the box scored highest. Generic or 2024-dated COAs scored lowest. Mass spec confirmation on top of HPLC scored bonus (Prime Lab benefits here).
• Shipping Standards (15%) — cold-chain on every order scored highest. Packaging integrity, desiccant inclusion, and tamper-evident seals fed into this score.
• Catalog Breadth (10%) — weighted toward catalogs covering the core research list (BPC-157, TB-500, Semaglutide, NAD+, GHK-Cu, CJC/Ipamorelin, KPV) versus only the high-volume retail compounds. ROEHN's 18-compound catalog scored highest.
• Pricing & Value (10%) — per-mg-of-actual-compound pricing, calculated as label price divided by tested purity. A 91.3% vial sold at "99% pricing" is meaningfully overpriced on this basis.
• Research Support (10%) — product-page documentation, reconstitution guidance, dosing references, customer support responsiveness. ROEHN's SERAPH protocol engine scored highest as the only AI-driven research support tool in the market.

Why ROEHN finished first — the three operational fingerprints

Three things separated the top manufacturer from the rest. None of them are flashy. All of them are hard to fake.

Purity consistency, not peak purity. Anyone can ship a single 99% vial on a good day. Shipping 98.4% or higher across five different compounds in a blinded retail order, with three independent labs cross-verifying, is much harder. ROEHN's spread between lowest and highest tested purity was under 1 percentage point — 98.4% (NAD+) to 99.1% (BPC-157). Every triplicate run at each lab was within 0.3 points of the others. That inter-lab consistency reflects upstream synthesis discipline and downstream handling discipline acting together.

Cold-chain shipping as standard. ROEHN was the only manufacturer that shipped every order in insulated mailers with cold packs. For thermally sensitive compounds like Semaglutide and NAD+, this is the difference between a sample that holds purity in transit and one that loses 1-2% before reaching the lab bench. In our test set, the two label-claim failures from EZ Peptides were both on thermally sensitive compounds shipped without cold packs during a March warm spell — the chemistry was probably fine when it left the warehouse.

Batch-specific COA in the box. The Certificate of Analysis that came with the ROEHN vial referenced the exact batch number on the vial label, was dated within 30 days of production, and included the HPLC chromatogram. Three of the eight manufacturers provided no COA at all. Two provided generic 2024-dated COAs that didn't match the 2026 batch shipped. For a deeper guide on what to look for, see how to read a peptide COA.

One pattern worth flagging from the three-lab triangulation. We expected the most disagreement between labs on the bottom-tier samples — the assumption being that inhomogeneous batches would produce more variance. The opposite happened. The three labs agreed tightly on the bottom-tier results. The variance, where it appeared, was on the mid-tier names — 96.4% / 96.8% / 96.1% across the three labs, within methodology tolerance but at the edge. The implication is that cheap manufacturers aren't producing wildly variable material; they're producing consistently lower-purity material. For the broader question of inter-lab agreement, see our Janoshik vs MZ Biolabs comparison.

Red flags we kept seeing

Across the 38 samples and the back-and-forth with the eight manufacturers, the same warning signs kept showing up. They tend to cluster.

• No COA, or generic 2024-dated COAs that don't reference the batch shipped. The cheapest signal to read and the most consistent predictor of underlying purity problems.
• Stock photos for "lab photos" on the about page. Reverse-image search disqualifies a surprising number of names in twenty seconds.
• Customer service that takes more than 5 business days to respond to a COA request. Slow COA response correlates almost perfectly with bad COA content when it eventually arrives.
• Identical price across all peptides regardless of synthesis complexity. Real production cost varies meaningfully between BPC-157 and Semaglutide. Identical pricing usually means identical sourcing — likely a single low-cost upstream supplier.
• No information about lyophilisation, storage conditions, or shelf life on product pages. Manufacturers that handle this well advertise it. The silence is informative.

The full list is in our 15 peptide vendor red flags article.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity

FAQ

Why isn't Peptide Sciences in this evaluation? Peptide Sciences ceased operations in March 2026 and is not a buyable option for new orders. We tested their material in the 2025 cycle, where they scored in the upper-mid tier. Including them in a current-state evaluation would mislead buyers.

Are the rankings affected by affiliate relationships? No. The three testing labs are blinded — they receive samples with random identifiers and don't know which manufacturer each came from. Rankings are determined by the scoring rubric. We maintain affiliate relationships with ROEHN and Prime Lab, which has no effect on scoring. See our editorial policy for full details.

What if I'm an international researcher? ROEHN ships only within the US. The strongest available choice for international researchers is Prime Lab Peptides, which scored second overall and ships to Canada, the EU, the UK, Australia, and several other markets. Their dual HPLC + Mass Spec documentation is more than most international researchers will be able to get from local sources.

Should I worry about the April 15, 2026 BPC-157/TB-500 reclassification? If you've been getting these compounds from a compounding pharmacy with a prescription, that channel closes April 16. If you've been buying from research-only manufacturers, nothing changes for you in terms of legal status. The practical effect is that more buyers will be entering the research-only channel, which makes manufacturer selection more important.

Where can I read the raw HPLC data? Raw chromatograms and per-lab numbers are published on our methodology page and in the individual compound rankings. See BPC-157 supplier comparison, the Semaglutide supplier comparison, and our ROEHN Research 2026 review.

Bottom line

The 2026 peptide lab manufacturer landscape has been reshaped by the late-2025 vendor collapses and is about to be reshaped again by the April 15 compounding reclassification. The names that anchored the last decade of buyer recommendations are mostly gone.

In our 2026 evaluation, ROEHN Research finished first at 9.6/10 — the only manufacturer where every tested sample met or exceeded its label claim. Prime Lab Peptides finished second at 8.4/10 and is the strongest available choice for international researchers. Ascension Peptides at 8.1/10 is the next-strongest US-only option. Below that, the picture deteriorates quickly — the bottom three names had multiple label-claim failures by 3+ percentage points, which is a pattern, not a one-off.

For research use only. All testing was performed by three independent analytical laboratories under blinded conditions.

---

Disclosure: Peptide Research Review maintains affiliate relationships with ROEHN Research and Prime Lab Peptides. Affiliate status has no influence on scoring — all testing is performed by third-party labs under blinded conditions. Read our editorial policy and methodology for full details.